PF546 THE SFGM‐TC MDS SCORE AT DAY 180 IS ASSOCIATED WITH POST‐TRANSPLANT OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROME WHO UNDERWENT CD34+ SELECTED ALLOGENEIC STEM CELL TRANSPLANT | Publicación